Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United KingdomBusiness Wire • 11/04/21
Data Presented at ACG Shows Guardant Health's Blood-Based Test Accurately Detects Early-Stage Colorectal CancerBusiness Wire • 10/25/21
Guardant Health to Report Third Quarter Financial Results on November 4, 2021Business Wire • 10/08/21
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage CancersBusiness Wire • 10/05/21
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage CancersBusiness Wire • 09/15/21
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung CancerGlobeNewsWire • 09/07/21
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations SummitBusiness Wire • 08/06/21
Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management UpdatesBenzinga • 08/06/21
Guardant Health's (GH) CEO Helmy Eltoukhy on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of DirectorsBusiness Wire • 08/05/21
Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.The Motley Fool • 08/01/21
Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/21
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During PandemicBusiness Wire • 07/20/21
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding RoundPRNewsWire • 07/19/21
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic ProfilingBusiness Wire • 06/22/21